Optimizing the management of congenital thrombotic thrombocytopenic purpura
cTTP management necessitates individualized care by a multidisciplinary team. Treatment of cTTP relies on ADAMTS-13 replacement, which may be more effectively delivered with rADAMTS-13 than with plasma infusions. Further studies are needed to evaluate its long-term safety, particularly during pregnancy, and to optimize treatment strategies.
Authors
- Senthil Sukumar (ORCID: https://orcid.org/0000-0002-0882-6793)
- Shruti Chaturvedi (ORCID: https://orcid.org/0000-0001-6832-2389)
- Scully Mf
- Melissa F. Glasner
- Spero R. Cataland
Institutions
- Johns Hopkins University (US)
- Baylor College of Medicine (US)
- Johns Hopkins Medicine (US)
- The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (US)
- Education & Research Foundation (US)
- Thrombosis Research Institute (GB)
- University College London (GB)
Publication Details
- Journal
- Research and Practice in Thrombosis and Haemostasis
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1016/j.rpth.2025.103270
- Primary Topic
- Complement system in diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Takeda Pharmaceuticals U.S.A.